Medicare Plans No Near-Term Change In Avastin Coverage Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS will monitor the issue and “evaluate coverage options” following FDA decision to rescind approval for Avastin’s use in metastatic breast cancer.